News

Provided that your portfolio is diversified to properly hedge against the risks associated with investing in stocks, it merely takes time, patience, and some well-thought-out picks to grow richer.

Axsome Therapeutics (NASDAQ: AXSM) wowed investors late last year with strong data from a phase 3 study of AXS-05, its candidate treatment for Alzheimer's disease agitation. AXS-05 met its primary

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

Shares of clinical-stage metabolism specialist Viking Therapeutics (NASDAQ: VKTX) were up by 12.4%, on abnormally high volume, as of 3:12 p.m. ET Tuesday afternoon. The big gain came after the

Biotech stocks have been on a wild ride this year. For instance, the bellwhether SPDR S&P Biotech ETF (NYSEMKT: XBI) has been up by as much as 9%, and down by as much as 12%, during just the first

Shares of Savara (NASDAQ: SVRA) rose more than 9% Tuesday morning after the company released first-quarter earnings. The stock is up more than 38% so far this year. Savara is a a clinical-stage phar

Investing in the cannabis industry is tricky. Some investors may be tempted to entirely shun the space based on its performance over the last two years. However, a few companies still offer

Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average

Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average

Shares of Sarepta Therapeutics (NASDAQ: SRPT) were skyrocketing 24.9% higher as of 10:37 a.m. ET on Monday. The huge gain came after the company announced Friday evening that a U.S. Food and Drug

On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Its shares popped by around 40%, leaving it up 12% in the last 30